Final Report Summary - AMCARE (Advanced Materials for Cardiac Regeneration (AMCARE))
Executive Summary:
Transformative therapies for Myocardial Infarction: The Advanced Materials for CArdiac REgeneration (AMCARE) project is a consortium of academic and industrial partners, which has received funding from the European Union (EU) to develop regenerative therapeutics for the treatment of a heart attack or myocardial infarction. The project began in November 2013 and finished in October 2017 and was tasked with the advancement of novel and transformative therapeutic strategies to address the significant healthcare burden posed by myocardial infarction.
The AMCARE partners derive from 5 countries within the EU. The consortium consisted of:
• 4 academic/research partners - The Royal College of Surgeons in Ireland (RCSI), Trinity College Dublin (TCD), the Eberhard Karls University, Tübingen (EKUT) and the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB)
• 5 small and medium enterprises (SMEs) – Celyad (formerly Cardio3 Biosciences), Explora Biotech, Adjucor, Innova and Contipro
• 1 multinational partner - Boston Scientific Limited
Each partner possessed a specific skill-set and expertise which contributed towards fulfilment of our common goal. More details on the partners and their roles in the consortium can be found at the ‘partners’ section on the AMCARE website www.amcare.eu.
The new approach proposed in AMCARE. Myocardial infarction (MI), more commonly known as a heart attack, occurs when a blood vessel feeding part of the heart muscle becomes blocked, depriving the muscle of blood leading to heart degeneration. If a person is overweight or obese, they are at a high risk of developing cardiovascular disease. MI represents an enormous source of mortality and morbidity globally. According to the European Society of Cardiology (ESC) one in six men and one in seven women in Europe will die from MI. According to the Irish Heart Foundation, heart disease or cardiovascular disease (CVD) is the most common cause of death in Ireland, accounting for 33% of all deaths. The largest number of these deaths are mainly due to myocardial infarction - at 5,000. 13% of premature deaths (under age 65) are from CVD.
The AMCARE project developed therapeutic technologies which aim to overcome some of the limitations of common treatments, with a view to maximising the effectiveness of regenerative therapies so that they can be used to treat MI patients in the clinic. AMCARE’s results have generated new knowledge with respect to treating the effects of myocardial infarction. The AMCARE technologies can be translated to the clinic and have positive impact on patients after having an MI.
www.amcare.eu
Transformative therapies for Myocardial Infarction: The Advanced Materials for CArdiac REgeneration (AMCARE) project is a consortium of academic and industrial partners, which has received funding from the European Union (EU) to develop regenerative therapeutics for the treatment of a heart attack or myocardial infarction. The project began in November 2013 and finished in October 2017 and was tasked with the advancement of novel and transformative therapeutic strategies to address the significant healthcare burden posed by myocardial infarction.
The AMCARE partners derive from 5 countries within the EU. The consortium consisted of:
• 4 academic/research partners - The Royal College of Surgeons in Ireland (RCSI), Trinity College Dublin (TCD), the Eberhard Karls University, Tübingen (EKUT) and the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB)
• 5 small and medium enterprises (SMEs) – Celyad (formerly Cardio3 Biosciences), Explora Biotech, Adjucor, Innova and Contipro
• 1 multinational partner - Boston Scientific Limited
Each partner possessed a specific skill-set and expertise which contributed towards fulfilment of our common goal. More details on the partners and their roles in the consortium can be found at the ‘partners’ section on the AMCARE website www.amcare.eu.
The new approach proposed in AMCARE. Myocardial infarction (MI), more commonly known as a heart attack, occurs when a blood vessel feeding part of the heart muscle becomes blocked, depriving the muscle of blood leading to heart degeneration. If a person is overweight or obese, they are at a high risk of developing cardiovascular disease. MI represents an enormous source of mortality and morbidity globally. According to the European Society of Cardiology (ESC) one in six men and one in seven women in Europe will die from MI. According to the Irish Heart Foundation, heart disease or cardiovascular disease (CVD) is the most common cause of death in Ireland, accounting for 33% of all deaths. The largest number of these deaths are mainly due to myocardial infarction - at 5,000. 13% of premature deaths (under age 65) are from CVD.
The AMCARE project developed therapeutic technologies which aim to overcome some of the limitations of common treatments, with a view to maximising the effectiveness of regenerative therapies so that they can be used to treat MI patients in the clinic. AMCARE’s results have generated new knowledge with respect to treating the effects of myocardial infarction. The AMCARE technologies can be translated to the clinic and have positive impact on patients after having an MI.
www.amcare.eu
